Pharmacists expand access to reproductive heaLthcare: PEARL study protocol.
Contraceptive Agents, Female
Drug Prescriptions
Female
Health Services Accessibility
Humans
Legislation, Drug
Oregon
Pharmaceutical Services
/ legislation & jurisprudence
Pharmacists
/ legislation & jurisprudence
Pregnancy
Pregnancy Rate
Pregnancy, Unplanned
Prospective Studies
Research Design
Retrospective Studies
Access to care
Continuation
Hormonal contraception
Pharmacists
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
01 Apr 2019
01 Apr 2019
Historique:
received:
19
02
2019
accepted:
24
03
2019
entrez:
3
4
2019
pubmed:
3
4
2019
medline:
16
5
2019
Statut:
epublish
Résumé
In 2016, Oregon became the first of eight states to allow pharmacists to directly prescribe hormonal contraception (HC), including the pill, patch, or ring, without a clinic visit. In the two years following this policy change, the majority of ZIP codes across the state of Oregon had a pharmacist certified to prescribe HC. We will utilize complementary methodologies to evaluate the effect of this policy change on convenient access to contraception (cost, supply dispensed), safety, contraceptive continuation and unintended pregnancy rates. We will conduct a prospective clinical cohort study to directly measure the impact of provider type on contraceptive continuation and to understand who is accessing hormonal contraception directly from pharmacists. We will concurrently conduct a retrospective analysis using medical claims data to evaluate the state-level effect of the policy. We will examine contraceptive continuation rates, incident pregnancy, and safety measures. The combination of these methodologies allows us to examine key woman-level factors, such as pregnancy intention and usual place of care, while also estimating the impact of the pharmacist prescription policy at the state level. Pharmacist prescription of HC is emerging nationally as a strategy to reduce unintended pregnancy. This study will provide data on the effect of this practice on convenient access to care, contraceptive safety and continuation rates.
Sections du résumé
BACKGROUND
BACKGROUND
In 2016, Oregon became the first of eight states to allow pharmacists to directly prescribe hormonal contraception (HC), including the pill, patch, or ring, without a clinic visit. In the two years following this policy change, the majority of ZIP codes across the state of Oregon had a pharmacist certified to prescribe HC.
METHODS
METHODS
We will utilize complementary methodologies to evaluate the effect of this policy change on convenient access to contraception (cost, supply dispensed), safety, contraceptive continuation and unintended pregnancy rates. We will conduct a prospective clinical cohort study to directly measure the impact of provider type on contraceptive continuation and to understand who is accessing hormonal contraception directly from pharmacists. We will concurrently conduct a retrospective analysis using medical claims data to evaluate the state-level effect of the policy. We will examine contraceptive continuation rates, incident pregnancy, and safety measures. The combination of these methodologies allows us to examine key woman-level factors, such as pregnancy intention and usual place of care, while also estimating the impact of the pharmacist prescription policy at the state level.
DISCUSSION
CONCLUSIONS
Pharmacist prescription of HC is emerging nationally as a strategy to reduce unintended pregnancy. This study will provide data on the effect of this practice on convenient access to care, contraceptive safety and continuation rates.
Identifiants
pubmed: 30935394
doi: 10.1186/s12913-019-4038-9
pii: 10.1186/s12913-019-4038-9
pmc: PMC6444429
doi:
Substances chimiques
Contraceptive Agents, Female
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207Subventions
Organisme : Laura and John Arnold Foundation
ID : 0
Références
Contraception. 2006 May;73(5):501-6
pubmed: 16627034
Contraception. 2006 Dec;74(6):463-70
pubmed: 17157103
Am J Obstet Gynecol. 2010 Mar;202(3):214-20
pubmed: 20207237
Stat Sci. 2010 Feb 1;25(1):1-21
pubmed: 20871802
Obstet Gynecol. 2011 Mar;117(3):551-7
pubmed: 21343757
Obstet Gynecol. 2011 Mar;117(3):558-65
pubmed: 21343758
Perspect Sex Reprod Health. 2011 Sep;43(3):173-80
pubmed: 21884385
Contraception. 2012 Oct;86(4):376-82
pubmed: 22520645
Biometrics. 2013 Sep;69(3):633-40
pubmed: 23724948
Am J Public Health. 2013 Oct;103(10):1772-9
pubmed: 23948010
Am J Obstet Gynecol. 2014 Jun;210(6):526.e1-9
pubmed: 24495671
Respirology. 2014 Jul;19(5):625-35
pubmed: 24889820
Obstet Gynecol. 2016 Jul;128(1):168-70
pubmed: 27275808
J Am Pharm Assoc (2003). 2018 Nov - Dec;58(6):608-613
pubmed: 30190201